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Melioidosis, dubbed the Vietnamese time bomb1 after 
reports of lengthy disease latency in war veterans, is 
caused by Burkholderia pseudomallei and manifests 
as acute, subacute, or chronic disease. Bacteraemic 
disease especially when associated with pneumonia 
is the most lethal form, especially if associated with 
septic shock, but infection with or without abscess 
formation can occur in any organ system. Although 
most presentations occur soon after exposure, the 
organism’s ability to evade host immune mechanisms 
and to survive and multiply in phagocytes2 gives rise to 
latency—latency of up to 62 years has been reported.3 
Seroprevalence rates vary widely but are highest in 
northeast Thailand, where most children show evidence 
of exposure.4 It remains unclear how many of those 
with serological evidence of exposure harbour latent 
B pseudomallei with the potential for subsequent 
activation. Several risk factors cause some people to 
have an increased risk of melioidosis, with diabetes 
being the most common.5
For those with culture-conﬁ rmed melioidosis, treat-
ment recommendations include an initial intensive 
intravenous course of at least 10 days with ceftazidime 
or a carbapenem.5 This course is followed by a so-called 
oral eradication phase of at least 3 months. The initial 
clinical response might indicate a need to modify the 
duration of the intensive phase, but the optimum 
antibiotic regimen and duration for eradication are 
uncertain. Recurrent melioidosis was noted in 13% 
of patients treated in Australia,6 but its prevalence 
has fallen over the past decade, possibly attributed to 
improved compliance, choice, and dosing of antibiotic 
regimens.7 Higher rates of recurrence in Thailand have 
been associated with inadequate duration of treatment.8
In The Lancet, Ploenchan Chetchotisakd and 
colleagues present ﬁ ndings from the MERTH trial,9 in 
which they enrolled 626 patients with melioidosis, 
randomly allocating them to receive trimethoprim-
sulfamethoxazole alone (the recommended regimen 
in Australia) or trimethoprim-sulfamethoxazole 
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eﬀ ectiveness of muscle training, the trial also shows the 
potential for prevention of prolapse symptoms through 
lifelong attention to pelvic ﬂ oor muscle exercise, and 
possibly intentional use of muscles to protect the pelvic 
ﬂ oor during physical strain, such as that inﬂ icted by 
heavy lifting. The results of this trial should encourage 
clinicians to refer women to physiotherapists, and to 
other health-care professionals who can implement 
behavioural and physical therapies for prolapse in a 
range of health-care settings.
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plus doxycycline (the recommended regimen in 
Thailand). During follow-up, they recorded no 
between-group diﬀ erence in the occurrence of culture-
positive recurrent cases (16 in the single-drug group, 
21 in the combination group; hazard ratio 0·81, 
95% CI 0·42–1·55), suggesting non-inferiority of the 
single-drug treatment (p=0·01). Furthermore, toxicity 
was higher in the combination group.
The study’s power calculations probably did not take 
into account the high rate of re-infection by a diﬀ erent 
genotype from the initial infection, rather than true 
relapse. Of recurrences with paired isolate typing 
undertaken (29 [78%] of 37 patients with culture-
conﬁ rmed recurrent melioidosis), 15 (52%) were due to a 
diﬀ erent genotype, which is much higher than previous 
reports—in a study of 921 patients in which detailed 
typing was used to characterise paired isolates from 
relapse cases, 26% were shown to be new infections.10 
It is tempting to postulate that at least some of these 
re-infections were actually recurrence from an original 
polyclonal infection, but the pronounced diﬀ erence 
in median time to re-presentation of 7 months (for 
relapse) versus 29 months (for reinfection) suggests 
otherwise. Previous work has also shown polyclonal 
infection to be a rare occurrence, happening in only 
1·5% of patients.11 Despite this unexpected ﬁ nding, even 
a subgroup analysis of same-genotype relapses lends 
support to the investigators’ conclusions.
MERTH had a treatment duration longer than 
generally recommended—20 weeks. Advocates of 
combination antibiotics for 3 months might therefore 
remain unconvinced without further research 
clarifying the optimum duration. However, several 
points support the study’s ﬁ ndings. Doxycycline 
might antagonise the eﬀ ects of trimethoprim-
sulfamethoxazole in vitro.12 Also, doxycycline mono-
therapy is associated with high rates of relapse.13 For 
many years, single-drug treatment with trimethoprim-
sulfamethoxazole has been used eﬀ ectively as 
eradication treatment in Australia.6 In view of the 
extended duration of eradication treatment necessary, 
compliance might be hampered by adverse events as 
reported in the combination treatment group in this 
trial. Patients in this group had a 40% rate of switching 
to second-line regimens due to adverse events.
B pseudomallei is an environmental saprophyte 
found in the soil and fresh surface water of tropical 
regions. Clinical trials in such settings are often 
diﬃ  cult, meaning that conditions of treatment are 
necessarily real-world. Melioidosis endemicity has been 
reported in dozens of tropical regions and cases are 
also imported to non-tropical areas, but numbers are 
generally small. Adequately powered clinical trials can 
be done only in highly endemic areas such as Thailand, 
with support from international organisations 
experienced in clinical trials. It is a disease of major 
public health importance in northeast Thailand, and is 
possibly the third most common cause of death due to 
an infection after HIV and tuberculosis, accounting for 
roughly 20% of community-acquired bacteraemia.5 The 
ﬁ ndings of MERTH should prompt a change in standard 
recommendations for the eradication treatment phase 
of melioidosis toward trimethoprim-sulfamethoxazole 
alone. However, many questions about optimum doses 
and duration remain, with some even suggesting 
that an extended intravenous phase might decrease 
the rate of relapse. Because B pseudomallei has such 
complex interactions with host immunity resulting in 
latency, diverse presentations, and high risk of disease 
relapse, future treatment guidelines might be equally 
complex and possibly stratiﬁ ed, related to disease 
site and severity, as well as host factors and initial 
treatment response.
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Countries around the world face a perfect storm of 
converging threats that might substantially increase 
the risk from infectious disease epidemics, despite 
improvements in technologies, communication, and 
some health systems. New pathogens emerge each 
year, some of which have high mortality and the 
potential for eﬃ  cient transmission—eg, severe acute 
respiratory syndrome (SARS),1 Middle East respiratory 
syndrome coronavirus,2 and avian inﬂ uenza A H7N9.3 
Existing pathogens are becoming resistant to available 
antibiotics and several are now resistant to virtually 
all available treatment.4 There is also the potential 
threat of intentional release of biological agents, 
which can be developed or synthesised biologically 
and disseminated at low cost and with little scientiﬁ c 
expertise. Moreover, the accelerated pace of 
globalisation ampliﬁ es these risks: a disease is just a 
plane trip away, and an outbreak anywhere is a threat 
everywhere.
One of the primary responsibilities of any 
government is to protect the health and safety of 
its people. There are three key elements of health 
security: prevention wherever possible, early detection, 
and timely and eﬀ ective response. Although many 
countries are now better able to manage infectious 
disease threats than in the past, these improvements 
have often been small in scale and limited in scope. The 
International Health Regulations (IHR), revised by WHO 
in 2005 to more directly address new and emerging 
epidemic threats,5 require all 194 signatory countries 
to improve capacity in these and other areas as part of 
their commitment to protecting health.6 Yet, at least 
80% of countries did not report full IHR compliance by 
the 2012 deadline.7
There is a perception in some quarters that tackling 
epidemic threats is less important than addressing 
major killers, such as HIV, tuberculosis, and malaria, 
and that international eﬀ orts to stop outbreaks might 
be more in the interest of high-income than of low-
income and middle-income countries.8 In fact, epidemic 
threats are potentially devastating to development 
through economic dislocation, decreased productivity, 
avoidable medical costs, loss of revenues from tourism 
and travel, and negative incentives for investment. The 
eﬀ ective implementation of measures to ensure global 
health security builds a ﬁ rm, broad-based public health 
foundation that promotes country self-suﬃ  ciency 
and can sustain health progress in any area in which 
a country decides to focus. Most fundamentally, 
addressing epidemic threats saves lives.
Rapid progress in health security is feasible if there is 
high-level political motivation, adequate investment, 
and technical expertise. After the devastating impact of 
SARS in 2003, China launched an ambitious programme 
to improve detection of new threats, strengthen 
response capacity, and report more transparently. The 
number of inﬂ uenza surveillance laboratories grew to 
more than 400, the Chinese National Inﬂ uenza Center 
was designated as the world’s ﬁ fth WHO Collaborating 
Centre for Reference and Research on Inﬂ uenza,9 the 
Chinese Center for Disease Control and Prevention 
(China CDC) was greatly strengthened with training 
of ﬁ eld epidemiologists and establishment of an 
Emergency Operations Centre, and mechanisms for 
rapid reporting to WHO were put in place. When the 
inﬂ uenza A H7N9 virus began causing human illness in 
February, 2013, China was quickly able to identify and 
sequence the genome, and share the sequence globally 
within days of the ﬁ rst report, which enabled a rapid 
start on development of diagnostics and a vaccine.
Many countries have improved health security by 
preventing avoidable epidemics, detecting outbreaks 
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